Ergoteles’s Maravai LifeSciences MRVI Stock Holding History

Ergoteles’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-28,212	Closed	-$395K	–	1322
2023 Q1	$395K	Buy	+28,212	New	+$405K	0.02%	817
2022 Q4	–	Sell	-75,597	Closed	-$1.93M	–	1723
2022 Q3	$1.93M	Buy	+75,597	New	+$1.9M	0.07%	285
2022 Q2	–	Sell	-10,000	Closed	-$353K	–	1866
2022 Q1	$353K	Buy	+10,000	New	+$335K	0.01%	790
2021 Q4	–	Sell	-126,584	Closed	-$6.21M	–	1466
2021 Q3	$6.21M	Buy	126,584 +107,284	+556%	+$5.23M	0.23%	119
2021 Q2	$805K	Buy	+19,300	New	+$748K	0.02%	586

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Ergoteles's MRVI Position: Q2 2023 in Review

Ergoteles sold out of Maravai LifeSciences (MRVI) in Q2 2023, closing a stake of 28,212 shares — an estimated $395K sold.

Ergoteles first reported a position in MRVI in Q2 2021 and held it in 5 quarters. The position peaked at $6.21M in Q3 2021. 221 funds tracked by Wall St. Rank hold MRVI as of Q2 2023.

Ergoteles reported no remaining Maravai LifeSciences position as of Q2 2023 after selling out during the quarter.
Ergoteles sold 28,212 Maravai LifeSciences shares in Q2 2023, an estimated $395K.
Ergoteles first reported a position in Maravai LifeSciences in Q2 2021 and held it in 5 quarters.
Ergoteles's Maravai LifeSciences position peaked at $6.21M in Q3 2021.
221 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.